TY - JOUR
T1 - Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in children
AU - Sakaguchi, Hirotoshi
AU - Takahashi, Yoshiyuki
AU - Watanabe, Nobuhiro
AU - Doisaki, Sayoko
AU - Muramatsu, Hideki
AU - Hama, Asahito
AU - Shimada, Akira
AU - Yagasaki, Hiroshi
AU - Kudo, Kazuko
AU - Kojima, Seiji
PY - 2012/5
Y1 - 2012/5
N2 - Background: Idiopathic pneumonia syndrome (IPS) is a severe complication that can occur after hematopoietic stem cell transplantation (HSCT) and is often associated with a fatal outcome despite intensive supportive care. Procedure: To assess the incidence and risk factors of IPS, we reviewed 251 consecutive patients (median age, 7.0 years) who received HSCT at the Department of Pediatrics, Nagoya University Hospital, between January 1990 and July 2009. Results: Twenty of 251 (cumulative incidence of IPS at 2 years after HSCT, 8.0%; 95% confidence interval (CI), 5.1-12.4%) patients developed IPS. The median duration from HSCT to diagnosis of IPS was 67 days (range, 12-486 days). Patients with IPS had significantly higher 5-year transplant-related mortality compared to patients without IPS (52% (95% CI, 19-77%) vs. 13% (95% CI, 5-25%), P<0.001), and the probability of 5-year overall survival was significantly worse for patients with IPS (42% (95% CI, 25-64%) vs. 68% (95% CI, 59-76%), P=0.01). By multivariate analysis, high risk in underlying disease (HR, 2.5; 95% CI, 1.0-6.7; P=0.05) and a busulfan-containing regimen (HR, 3.5; 95% CI, 1.3-9.9; P<0.01) were identified as the independent risk factors for developing IPS. Conclusion: The prophylactic strategies for IPS in patients with these risk factors were warranted.
AB - Background: Idiopathic pneumonia syndrome (IPS) is a severe complication that can occur after hematopoietic stem cell transplantation (HSCT) and is often associated with a fatal outcome despite intensive supportive care. Procedure: To assess the incidence and risk factors of IPS, we reviewed 251 consecutive patients (median age, 7.0 years) who received HSCT at the Department of Pediatrics, Nagoya University Hospital, between January 1990 and July 2009. Results: Twenty of 251 (cumulative incidence of IPS at 2 years after HSCT, 8.0%; 95% confidence interval (CI), 5.1-12.4%) patients developed IPS. The median duration from HSCT to diagnosis of IPS was 67 days (range, 12-486 days). Patients with IPS had significantly higher 5-year transplant-related mortality compared to patients without IPS (52% (95% CI, 19-77%) vs. 13% (95% CI, 5-25%), P<0.001), and the probability of 5-year overall survival was significantly worse for patients with IPS (42% (95% CI, 25-64%) vs. 68% (95% CI, 59-76%), P=0.01). By multivariate analysis, high risk in underlying disease (HR, 2.5; 95% CI, 1.0-6.7; P=0.05) and a busulfan-containing regimen (HR, 3.5; 95% CI, 1.3-9.9; P<0.01) were identified as the independent risk factors for developing IPS. Conclusion: The prophylactic strategies for IPS in patients with these risk factors were warranted.
UR - http://www.scopus.com/inward/record.url?scp=84857860777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857860777&partnerID=8YFLogxK
U2 - 10.1002/pbc.23298
DO - 10.1002/pbc.23298
M3 - Article
C2 - 21922645
AN - SCOPUS:84857860777
SN - 1545-5009
VL - 58
SP - 780
EP - 784
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 5
ER -